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Purpose: To investigate the profile of cytokines in tear fluid of patients after allogeneic stem cell transplantation (allo-
SCT) and determine their relation to the presence and manifestations of ocular graft-versus-host disease (GvHD).
Methods: In this cross sectional study tear fluid was collected in 34 consecutive adult patients that previously underwent
allo-SCT (16 with ocular GvHD and 18 without) and 16 age- and gender-matched healthy controls using the Schirmer
test under local anesthesia. Tear fluid was analyzed by multiplex immunoassay for the presence of interleukin (IL)-2,
IL-4, IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-α and interferon (IFN)-γ. Levels of measured cytokines were
correlated with the findings in slit lamp examination and the Ocular Surface Disease Index (OSDI).
Results: The levels of IL-6 and IFN-γ in tear fluid in ocular GvHD patients were significantly elevated in comparison to
patients without ocular GvHD and healthy controls (p<0.005 for each) The levels of IFN-γ correlated with the Schirmer
score (r=-0.48, p<0.0001) and tear break up time (TBUT; r=-0.38, p=0.03). Tear IL-6 levels correlated with complaints
of dry eyes (r=0.39, p=0.02), tear production (r=-0.59, p<0.0001), fluorescent staining of the cornea (r=0.42, p=0.01), and
with the OSDI score (r=0.40, p=0.005).
Conclusions: IL-6 and IFN-γ were elevated in tear fluid of patients with ocular GvHD and correlated with different
symptoms of dry eye disease, suggesting that IFN-γ is elevated during the early stages and IL-6 is involved in later stages
of ocular GVHD and exhibits moreover an association with its severity.
Hematopoietic  stem  cell  transplantation  (SCT)  is  the
treatment of choice for many life-threatening malignant and
non-malignant hematologic diseases. Allogeneic SCT (allo-
SCT) is commonly accompanied by graft-versus-host disease
(GvHD), a multi-organ systemic disease associated with high
morbidity and mortality. Ocular GvHD predominantly affects
the  anterior  ocular  segment  and  manifestations  include
conjunctival or corneal epithelial changes, Meibomian gland
dysfunction  and  dry  eye  disease  (DED)  manifesting  as
keratoconjunctivitis  sicca  (KCS)  [1,2].  KCS  is  the  most
frequently occurring symptom of ocular GvHD and until now
its  presence  is  used  to  diagnose  ocular  GvHD  [3].  The
pathogenesis  of  ocular  GvHD  has  not  yet  been  clarified.
Cytokines  have  been  suggested  to  play  a  major  role  in
development of systemic and ocular GvHD and increased
levels of interleukin (IL)-6 and interferon gamma (IFN-γ)
have been observed in serum in patients with systemic acute
GvHD [4].
Increased levels of pro-inflammatory cytokines in tear
fluid, including interleukin (IL)-6 and IFN-γ were noted in
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DED of various origins, nonetheless their role in DED is not
yet clarified [5,6].
The purpose of this study was to determine the cytokine
levels in tear fluid in patients after allo-SCT and to identify
their relation to the presence of ocular GvHD and clinical
symptoms of DED.
METHODS
The study was performed in accordance with the Declaration
of Helsinki and with the approval of the local Institutional
Review Board.
Patients: In this cross-sectional pilot study, we included
34 consecutive allo-SCT patients referred to the Department
of  Ophthalmology  of  the  University  Medical  Centre  of
Utrecht  (UMCU).  Patients  with  ocular  comorbidity  and
patients with a mean Schirmer of ≤1 mm in 5 min were
excluded (n=1). Patients consulted our ophthalmology clinic
3 months after SCT for screening or at any other time if they
had ocular complaints after SCT. Sixteen gender- and age-
matched healthy volunteers with no history of ocular disease,
current  systemic  and  ocular  infection  were  included  as
controls.
Diagnostic  criteria:  All  patients  underwent  a  visual
acuity test, slit-lamp examination and a Schirmer test as part
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797of the standard examination for ocular GvHD. The diagnosis
of ocular GvHD was based on the National Institute for Health
(NIH) consensus criteria, which combines the presence of
systemic GvHD manifestations with either a mean Schirmer
test value ≤5 mm in 5 min or newly developed slit-lamp-
confirmed KCS with mean score of Schirmer test between 6
and 10 mm in 5 min (with local anesthesia [Oxybuprocain
0.4%]) [3]. The diagnosis of KCS with the slit-lamp was made
based on the presence of fluorescent staining of the cornea,
decreased tear break up time (TBUT) and complaints of dry
eyes such as grittiness and blurring of vision. According to
NIH  consensus  criteria  [3],  blepharitis,  Meibomian  gland
dysfunction, and chemosis were not taken into account for the
diagnosis of ocular GvHD. Patients and controls completed
the Ocular Surface Disease Index (OSDI) questionnaire to
determine  the  subjective  ocular  symptoms  as  described
previously [7,8].
Tear  sample  collection:  The  tear  production  was
determined with a Schirmer test under local anesthetic drops
(Oxybuprocaine HCl, 0.4%) applied 3 min before applying
the  strip.  The  Schirmer  strip  (Schirmer  Tear  Test  Strips;
Biotech Vision Care Pvt. Ltd., Ahmedabad, Gujarat, India)
was  placed  in  the  lateral  lower  conjunctival  sac  and  the
participants were instructed to close their eyes. After 5 min
the strips were removed and the tear production recorded in
millimeters. Each Schirmer strip was immediately placed in
an Eppendorf plastic tube (Sarstedt, Numbrecht, Germany)
and  diluted  1:20  with  phosphate-buffered  saline  solution
(PBS, pH=7.4). The strips were incubated at 4 °C overnight
and stored at –80 °C until use.
Cytokine concentration analysis: The tear fluid of the eye
with the lowest Schirmer score of each subject was analyzed.
If the values in both eyes were equal, the Schirmer strip of the
right eye was chosen for analysis. The levels of IL-2, IL-4,
IL-6,  IL-10,  IL-17A,  TNF-α,  and  IFN-γ  in  tears  were
measured  by  multiplex  immunoassay  (Cytometric  Bead
Array;  BD  Biosciences,  San  Jose,  CA)  according  to  the
manufacturer’s protocol. Detection limits for IL-2, IL-4, IL-6,
IL-10, IL-17A, TNF-α, and IFN-γ were 2.6, 4.9, 2.4, 4.5, 18.9,
3.8,  and  3.7  pg/ml,  respectively.  Concentrations  were
calculated from the generated standard curves.
Statistical analysis: Statistical analysis was performed
with  the  SPSS  software  package  (SPSS  version  15  for
Windows;  Chicago,  IL).  Analysis  of  variance  (ANOVA),
Mann–Whitney U test, and Fisher’s exact test were used to
analyze  group  differences.  Correlation  between  clinical
parameters  and  interleukin  levels  was  determined  by
Spearman  rank  test.  P-values  were  adjusted  for  multiple
comparisons using a Bonferroni’s correction. A p-value less
than 0.05 was regarded statistically significant.
RESULTS
Study  population:  Study  group  demographic  details  are
summarized in Table 1; 34 patients after allo-SCT, 16 with
ocular GvHD and 18 patients without ocular GvHD were
included. The healthy controls (n=16; mean age: 48.0±15.1,
male/female ratio: 11/5) were age- and gender- matched to the
patients group. The median interval time between the last allo-
SCT and clinical examination was 37.2 months (interquartile
range [iq] range 68) for the ocular GvHD group and 3 months
(iq range 3) for the no ocular GvHD group (p=0.007).
Diagnostic clinical tests: Of all patients with ocular GvHD
14/16 (88%) had complaints of dry eyes, 6/16 (38%) had a
decreased TBUT and in 9/16 (56%) fluorescein staining of the
cornea was seen.
The mean Schirmer score was lower in the ocular GvHD
group (4.4±2.0 mm) in comparison to the no ocular GvHD
group (16.2±7.5 mm, p<0.0001) and the healthy control group
(22.1±7,  p<0.0001).  The  median  OSDI  score  was
significantly impaired in the ocular GvHD compared to the
two other study groups (Table 2).
Cytokine tear levels: Results of the tear cytokine levels are
shown in Table 2. IL-6 was detected in the tear fluid of 15/34
(44%) allo-SCT patients and in 1/16 (6%) of healthy controls
(p<0.0001).  The  median  level  of  IL-6  in  tear  fluid  was
significantly elevated in the ocular GvHD group compared to
the no ocular GvHD group (p=0.005), and the control group
(p<0.0001).  IL-6  levels  in  patients  without  ocular  GvHD
patients and healthy controls did not differ (p=0.162). IFN-γ
was detected in tear fluid in 8/16 (50%) ocular GvHD patients.
IFN-γ could not be detected in the other groups. IL-2, IL-4,
IL-10, IL-17, and TNF-α could not be detected in any of the
samples. The mean age of patients in which IL-6 (53.8±13) or
IFN-γ (53.9±12) was detected, was not different from patients
in whom no IL-6 (48.5±14) or IFN-γ (43.6±16) could be
detected (p=0.28; p=0.11).
Correlation between cytokines and clinical manifestations of
ocular GVHD: Correlation analysis was performed between
tear cytokine levels and symptoms of ocular GvHD for IL-6
and IFN-γ. No significant correlation could be found between
the levels of IFN- γ and IL-6 (r=0.23, p=0.189).Tear IL-6
levels correlated with complaints of dry eyes (r=0.39, p=0.02),
tear  production  measured  by  Schirmer  test  (r=-0.59,
p<0.0001),  fluorescent  staining  of  the  cornea  (r=0.42,
p=0.01), and OSDI score (r=0.40, p=0.005). IL-6 did not
correlate with TBUT (r=-0.03, p=0.88). The levels of IFN-γ
correlated with the tear production measured by Schirmer test
(r=-0.48, p<0.0001) and TBUT (r=-0.38, p=0.03). However,
IFN-γ did not correlate significantly with complaints of dry
eyes  (r=0.12,  p=0.48),  fluorescent  staining  of  the  cornea
(r=0.10, p=0.57), or OSDI scores (r=0.16, p=0.61).
DISCUSSION
In this study, significantly elevated IL-6 and IFN-γ levels in
tear fluid in patients with ocular GvHD were detected. These
cytokines  were  associated  with  different  clinical  features:
IL-6 with complaints of dry eyes, OSDI scores and corneal
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798staining whereas IFN-γ showed an association with decreased
TBUT  and  low  Schirmer  test  score.  These  results  might
demonstrate that IFN-y is elevated in the early stage of ocular
GvHD and that IL-6 is elevated later in the disease and is
associated with the severity of ocular GvHD.
The measurements of tear production using Schirmer test
might reveal variable results [9]. When applying the strips
without  previous  anesthesia,  the  results  are  a  subject  to
variability  due  to  reflex  tearing  and  when  using  prior
anesthesia, the residual amount of topical anesthetics might
influence the Schirmer values. To minimize these variable
measurements, we have chosen to apply anesthetic drops to
measure  a  basal  tear  production  and  further  included  a
standard interval between the application of anesthetic drops
and Schirmer test to minimize the influence of their possible
residual presence.
IFN-γ is a T-cell associated cytokine that plays a major
role in the pathogenesis of GvHD [10]. IL-6 is known to
contribute to GvHD severity [11] but has also been reported
to be correlated with disease onset [12].
The  current  knowledge  about  the  involvement  of
interleukins in ocular GvHD is very limited. The conjunctiva
is known to be one of the target organs in the T-cell mediated
GvHD, resembling complex autoimmune fibrotic processes
[13-15].
Ogawa et al. [13] reported that donor-derived cluster of
differentiation (CD)34+ stromal fibroblasts were present in
the lacrimal gland of DED patients after allo-SCT. Subsets of
stromal fibroblasts can function as antigen presenting cells
TABLE 1. GENERAL CHARACTERISTICS OF PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT).
Patient characteristics Total, allo-SCT
patients (n=34)
Ocular GvHD*
(n=16)
No Ocular GvHD
(n=18)
Mean age (yrs)±SD (Minimum,
maximum)
51.5±13.8 (18–71) 50.1±15.8 (23–71) 52.7±12.1 (18–64)
Gender, n (%)
Male 22/34 (65%) 13/16 (81%) 9/18 (50%)
Female 12/34 (35%) 3/16 (19%) 9/18 (50%)
Follow-up last transplantation, n (%)
≤100 days 15/34 (44%) 3/16 (19%) 12/18 (67%)
>100 days 19/34 (56%) 13/16 (81%) 6/18 (33%)
Type of transplant, n (%)
Matched related donor 11/34 (32%) 9/16 (56%) 2/18 (11%)
Matched unrelated donor 23/34 (68%) 7/16 (44%) 16/18 (89%)
TBI, n (%)
Yes 27/34 (79%) 13/16 (81%) 14/18 (78%)
Unknown 2/34 (6%) 1/16 (6%) 1/18 (6%)
TBI and chemotherapy (ATG or FLU)
Yes 27/34 (54%) 13/16 (81%) 14/18 (78%)
Unknown 2/34 (4%) 1/16 (6%) 1/18 (6%)
Type of disorder, n (%)
Multiple myeloma 10/34 (29%) 5/16 (31%) 5/18 (28%)
AML 9/34 (26%) 1/16 (6%) 8/18 (44%)
NHL 5/34 (15%) 3/16 (19%) 2/18 (11%)
ALL 3/34 (9%) 1/16 (6%) 2/18 (11%)
CLL 1/34 (3%) 1/16 (6%) 0/18 (0%)
HL 1/34 (3%) 1/16 (6%) 0/18 (0%)
CML 1/34 (3%) 1/16 (6%) 0/18 (0%)
Other 4/34 (12%) 3/16 (19%) 1/18 (6%)
        n, Number of patients; FLU, Fludarabine; CML, Chronic myelcytic leukemia; ATG, Anti-thymocyte globulin; ALL, Acute
        lymphblastic leukemia; Allo-SCT, allogeneic stem cell transplantation; AML, Acute myeloblastic leukemia; CLL, Chronic
        lymphocytic leukemia;  GvHD, Graft-verus-Host-Disease; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; SD,
        standard deviation; TBI, Total body irradiation. *diagnosed according to the National Institute for Health consensus criteria
        [3].
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800and activate donor T-cells, which may result in the formation
of pro-inflammatory cytokines like IL-6 and IFN-γ [13].
Elevated levels of IL-6 and IFN-γ in tears were previously
found  and  were  associated  with  DED  seen  in  different
etiologies, including Sjorgren’s disease [5,16,17]. IFN-γ is a
crucial cytokine in the induction of GvHD [4]. Recently, a
central role for IFN-γ-producing natural killer cells in the
induction of DED was demonstrated by Chen et al. [18], which
is entirely consistent with our findings of association of IFN-
γ with tear production and TBUT but not being associated with
the overall surface damage.
The  measured  tear  IL-6  concentrations  in  our  study
correlate with the subjective complaints tear production and
corneal damage, suggesting that the increased IL-6 in tear
fluid may be a result of the progressing DED. Lam et al. [19]
concluded that IL-6 correlated with the severity of symptoms
and signs of tear dysfunctional syndrome, which is consistent
with our findings. The exact source of IL-6 production in
patients  with  DED  is  not  known;  however  IL-6  can  be
produced by many cells including monocytes, macrophages
and fibroblasts [20]. IL-6 is a potent cytokine and mediator in
local and systemic inflammation and has effect on B cells and
T cells [20-22]. IL-6 can also promote the differentiation of
Th17 T cells, important regulators of autoimmune responses,
which occur in DED and acute GvHD [21,23,24]. Much of
our understanding of IL-6 and Th17 responses in GvHD come
from  mice  models.  Th17  cells,  with  the  characteristic
production of IL-17, can mediate pathology associated with
GvHD in mice [24]. In multiple mouse strains blocking of
IL-6  signaling  dramatically  attenuates  GvHD  and  Th17
responses  [11,25].  However  Th17  responses  may  not  be
prerequisite  for  the  development  of  GvHD  [26].  It  was
suggested that posttransplantational epigenetic modifications
of donor Th17 cells, which alter their cytokine production,
lead to loss of IL-17 and increase in IFN-y producing cells
[24]. In contrast to the mouse models, blocking of the IL-6
receptor in humans does not alter dendritic cell maturation,
allogeneic T cell proliferation, or Th1/Th17 responses [27].
The role of IL-6 in ocular GvHD in humans may be beyond
Th17 promoting and differ between mice models and human
disease. Although a recent study with patients with dry eyes
in  aqueous-deficient  patients  suggested  that  elevated  IL-6
levels in tear fluid had to be considered as a Th17 promoting
response, the levels of IL-17 were not assessed [16]. We detect
increased levels of IL-6 and IFN-γ in tear fluid of ocular
GvHD, but were unable to detect IL-17 in any of the samples.
It  has  been  observed  that  IL-6  also  promotes  the
differentiation  of  B  cells  and  the  induction  of  antibody
production  [28].  B  cells  play  an  important  role  in  the
development of GvHD which accounts for the effectiveness
of B-cell depletion in the treatment of GVHD [29]. The role
of IL-6 and the involvement of Th17 responses in human
ocular GvHD remains to be elucidated.
In our study the group with ocular GvHD had a longer
time interval between the measurements of cytokines than the
group without ocular GvHD. This time difference can be
explained  by  the  fact  that  patients  without  ocular  GvHD
visited  our  OPD  three  months  after  SCT  for  screening
purposes while patients with ocular GvHD visited our OPD
for  their  treatment  of  ocular  GvHD.  However  this  time
difference has no impact on the main message of this study.
Confounders  such  as  treatment  with  radiotherapy  and
chemotherapy and other medication were not taken in account
due to the small number of patients.
Ocular GvHD is a serious ocular disorder significantly
affecting the quality of life of patients following allo-SCT.
The pathogenesis is unknown and the current therapy includes
symptomatic regimens with lubricant and anti-inflammatory
medications.  To  develop  preventive  and/or  curative
treatments the further clarification of pathogenesis of this
disorder  is  necessary.  In  addition,  ocular  GvHD  offers  a
unique opportunity to study the early onset of DED since it
develops in many individuals after allo-SCT and the moment
of onset is predictable. In contrast to former studies of DED,
tear fluid analyses in ocular GvHD offer a unique opportunity
for studying the pathogenesis of DED by determination of
specific  inflammatory  mediators  in  diverse  phases  of  this
disorder. Giving the cross-sectional nature of this pilot study
and its results, future prospective studies can concentrate on
the changes occurring in tear fluid over time, before and after
allo-SCT (in the preclinical stages of ocular GvHD and before
the onset of DED) to identify the initial stages of ocular GvHD
and determine the value of specific cytokines in the initiation
and continuation of DED in ocular GvHD.
The results of this small study seem promising and show
that IL-6 and IFN-γ were elevated in tear fluid of patients with
ocular GvHD and correlated with different symptoms of dry
eye disease.
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